Progression of pain at its worst was less common in the enzalutamide group than in the placebo group at week @ ( @ -LSB- @ % -RSB- of @ vs @ -LSB- @ % -RSB- of @ ; p < @ ) , but not at week @ ( @ -LSB- @ % -RSB- of @ vs @ -LSB- @ % -RSB- of @ ; p = @ ) .